Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SatisfACtion: 225Ac-PSMA-R2 in mHSPC and mCRPC
NCT05983198Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2023
- Primary completion
- Mar 2031
- Countries
- 4
01
Overview
Phase 1, open-label trial of 225Ac-PSMA-R2 in prostate cancer (PCa) (3 arms), sponsored by Novartis. Primary endpoints: Dose-Limiting Toxicities at 6 weeks, Adverse Events and Serious Adverse Events at 15 months and 2 more. Started Nov 2023; status: active, not recruiting.
02
Drugs
225Ac-PSMA-R2
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05983198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05983198.